Ali Samii

Ali Samii practices at Seattle VA Medical Center - Behavioral Health in Seattle, Washington.

Ali Samii's NPI, 1811087760, was assigned on October 13, 2006. Ali Samii graduated from McGill University Faculty of Medicine in 1989. Ali Samii holds Washington license MD00036468.

Ali Samii's primary practice is Seattle VA Medical Center - Behavioral Health, at 1660 South Columbian Way Mail Stop S-116-ATC, Seattle, WA 98108. The practice phone is (206) 277-3318.

Ali Samii's primary practice is Seattle VA Medical Center - Behavioral Health in Seattle, Washington. Ali Samii is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians. Dmand AI also links Ali Samii to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Ali Samii practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Ali Samii's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Ali Samii is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Ali Samii's licenses on file in 2 states: Washington and California.

Dmand AI lists essential tremor, neuropathy and parkinson's disease among the conditions Ali Samii treats.

CMS data shows 200 Medicare services from Ali Samii across 3 procedure codes in 2024, for 107 Medicare patients. Medicare paid $14,448 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 107 Medicare patients who saw Ali Samii in 2024. The largest group is 65 to 74, with 45 patients. 63% of them have parkinson's disease, and 53% have high cholesterol. Their average risk score is 1.36, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Ali Samii's median patient age at 73, with 47% women.

In 2024, Ali Samii wrote 562 Medicare Part D claims for 77 patients. 94% of them were for generic drugs. CMS names the drug for 507 of them, across 13 drugs with 11 or more claims each, at $64,333 in total drug cost. In 2023, CMS named 470 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Ali Samii for performance year 2024, reported through an alternative payment model (APM). Ali Samii accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Ali Samii as offering telehealth.

Dmand AI links 65 papers to Ali Samii, published from 2006 to 2022. 2015 was the busiest year, with 4. The most frequent topics are Parkinson Disease, Genetic Predisposition to Disease and Genotype. Ali Samii has published most often in Neurology. Ali Samii's most frequent co-authors are Cyrus Parse Zabetian, MD, John W. Roberts, MD and Pinky Agarwal, MD.

Dmand AI links Ali Samii to 4 clinical trials. 2 are still active or recruiting. Conditions studied include Huntington Disease, Chorea and Machado-Joseph Disease.

CMS Open Payments shows 4 general payments to Ali Samii from 3 drug and device companies from 2017 to 2025. Honoraria make up the largest share, 97% of the total. Amneal Pharmaceuticals LLC paid the most, $1,150.

Dmand AI lists 1 award for Ali Samii.

Ali Samii graduated from McGill University Faculty of Medicine in 1989. Ali Samii is a member of AAN.

Ali Samii is in network with 16 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.